Drug Database
IN

influenza vaccine

✓ Approved

Sinovac Biotech · Vaccine · Vaccine

What is influenza vaccine?

influenza vaccine is a vaccine developed by Sinovac Biotech. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanySinovac Biotech
Drug ClassVaccine, Large Molecules
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Sinovac Biotech

Related Research Articles

PubMedInfectious diseases and therapy2026-10-15

A Phase 2 Trial Evaluating the Immunogenicity and Safety of an mRNA-Based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.

Moldt Brian B, Ubeda Rafael A RA, Murray Alexander V AV, Tima Giresse G et al.

Influenza vaccines targeting both hemagglutinin (HA) and neuraminidase (NA) might offer broader protection than current vaccines, which primarily target HA. This randomized phase 2 study evaluated the immunogenicity and safety of an investigational mRNA-based trivalent seasonal influenza vaccine encoding HA and NA from A/H1N1, A/H3N2, and B/Victoria (FLUm3HA-3NA). Participants aged 18-64 years (younger adults) or 65-85 years (older adults) received one of several mRNA vaccine formulations-each containing different influenza A and B HA mRNA doses-or an age-appropriate licensed seasonal influenza vaccine as a comparator. Four formulations per age cohort were tested in part 1 of the study, and one formulation per age cohort in part 2. Day-29 hemagglutination inhibition (HI) and NA inhibition (NI) responses were assessed as primary and secondary endpoints, respectively, safety/reactogenicity as the secondary, and virus neutralization as the tertiary endpoint. A total of 250 younger and 260 older adults were vaccinated in part 1; 161 and 162, respectively, in part 2. All FLUm3HA-3NA formulations induced HI, NI, and neutralizing responses above baseline. In part 1, HI responses against A/H1N1 and A/H3N2 were similar or higher after FLUm3HA-3NA than after comparator vaccination in both age groups. For B/Victoria, HI responses were lower or similar versus comparator vaccination in younger adults and similar or higher in older adults. In part 2, HI responses were similar or higher with FLUm3HA-3NA versus comparators for A/H1N1 and A/H3N2, and lower for B/Victoria in both age groups. In both study parts and both age groups, NI titers were higher for all three strains with FLUm3HA-3NA versus comparators, and neutralizing titers were similar or higher for A/H1N1 and A/H3N2 and similar for B/Victoria. No safety concerns were identified. FLUm3HA-3NA induced HI, NI, and neutralizing responses, with an acceptable safety profile. The results support further development, including optimization of the influenza B HI response. ClinicalTrials.gov: NCT06431607.

PMID 42875682
Read full article →
PubMedFrontiers in immunology2026-10-15

Myeloid cell expression of the VDR and parathyroid hormone control the host response to influenza infection in mice.

Tang Mengzhu M, Froelich Nicole E NE, Hanna Nicholas J NJ, Weaver Veronika C VC et al.

Respiratory infections caused by seasonal influenza viruses remain a major global health burden. Vitamin D receptor (VDR) signaling regulates immune responses, but the role of the VDR and its interaction with parathyroid hormone (PTH) in host resistance to H1N1 influenza infection is not understood. Global VDR knockout (KO) mice, or myeloid (M) deletion of the VDR (M-VDR KO) and the respective wildtype (WT) littermates were infected with H1N1 influenza virus. Additional experiments treated WT mice with intermittent PTH or vehicle and then infected them with a H1N1 influenza A virus. Disease severity, mortality, viral burden and clearance, lung pathology, and inflammatory cytokine responses were evaluated. H1N1 influenza infection of WT mice resulted in non-lethal disease, whereas VDR KO mice had 21% mortality, delayed viral clearance, more severe symptoms and lung pathology. The increased severity of respiratory disease was accompanied by higher type I and II interferon responses in the lungs. M-VDR KO mice had increased disease severity and delayed viral clearance compared to WT littermates. PTH-treated WT mice had increased clinical scores, influenza M gene, and cytokine responses compared to vehicle treated WT mice. The work describes a novel paradigm in which the vitamin D-PTH axis governs host resistance to influenza virus disease by controlling the amount of inflammation and the amount of virus in the lung. In addition, the data suggest that VDR expression in myeloid cells is critical for controlling the early innate immune response to influenza viruses.

PMID 42876719
Read full article →
PubMedInfectious diseases and therapy2026-10-15

A Phase 1/2 Trial Evaluating the Safety and Immunogenicity of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.

De Coster Ilse I, Cardona Jose F JF, Ferguson Murdo M, Leroux-Roels Isabel I et al.

Hemagglutinin (HA) is the principal immunologic target of most licensed seasonal influenza vaccines. Targeting both HA and neuraminidase (NA) might improve vaccine effectiveness. This randomized phase 1/2 study evaluated an investigational mRNA-based quadrivalent seasonal influenza vaccine, encoding HA and NA of A/H1N1, A/H3N2, B/Victoria, and B/Yamagata (FLUm4HA-4NA). In phase 1, adults aged 18-50 years received either one of twelve mRNA vaccine formulations of varying HA-only or HA and NA mRNA doses, or a licensed quadrivalent seasonal influenza comparator. In phase 2, participants aged 18-64 years (younger adults) and 65-85 years (older adults) received FLUm4HA-4NA (three groups per age category, with different HA/NA mRNA doses) or age-appropriate licensed quadrivalent comparator. Primary endpoints were safety/reactogenicity, and hemagglutination inhibition [HI] and NA inhibition [NI] responses against the four seasonal strains at day 29. Cross-reactive HI/NI responses against drifted strains, virus neutralization, and HA-/NA-specific cell-mediated immunity were evaluated in phase 2 as tertiary objectives. A total of 293 participants (21-25 per group) were vaccinated in phase 1, 480 younger (108-137 per group) and 483 older adults (117-125 per group) in phase 2. Solicited events were more frequent with FLUm4HA-4NA than comparators and were mostly short-lived and mild or moderate. No deaths or vaccine-related serious adverse events were reported. Post-vaccination HI and neutralizing titers in the FLUm4HA-4NA groups were similar or higher for the A strains and lower for the B strains versus comparators. NI responses exceeded those of comparators for all four strains. HI and NI titers against evaluated drifted A strains were similar or higher after FLUm4HA-4NA than after comparator vaccination. HA-specific CD4+ and CD8+ T-cell responses were generally higher after FLUm4HA-4NA than comparator vaccination. FLUm4HA-4NA showed an acceptable safety profile and humoral and cellular immunogenicity in the study population, supporting further development and formulation optimization to improve influenza B HI responses. ClinicalTrials.gov: NCT05823974; euclinicaltrials.eu: 2022-502308-66-00.

PMID 42875683
Read full article →
PubMedPediatric transplantation2026-10-15

First Split Liver Transplantation Using VitaSmart Hypothermic Machine Perfusion in the United States.

Kahan Anastasia M AM, van der Schyff Francisca F, Robinson Todd T, Rodriguez Ivan I et al.

Dynamic perfusion techniques are increasingly used in liver transplantation to improve graft preservation and support preimplantation assessment. Its reported use in split liver transplantation remains limited. We report the first use of the VitaSmart hypothermic perfusion device for graft preservation during ex situ split in the United States, resulting in the successful transplantation of a right trisection graft into an adult recipient and a left lateral section graft into a pediatric recipient. A deceased donor liver was split into a right trisection graft for an adult recipient and a left lateral segment graft for a pediatric recipient. Both grafts underwent VitaSmart hypothermic oxygenated perfusion. Donor, graft, perfusion, operative, and early postoperative outcomes were reviewed. The adult recipient was a 63-year-old man with metabolic dysfunction-associated steatohepatitis cirrhosis. The pediatric recipient was a 4-year-old female with Joubert syndrome, congenital hepatic fibrosis with portal hypertension, and prior renal transplantation. The right trisection graft weighed 1001 g, with an estimated graft-to-recipient weight ratio of 1.1. Implantation was performed with bicaval, portal vein, hepatic artery, and duct-to-duct biliary anastomoses. Reperfusion was uneventful, with uniform graft perfusion, normal intraoperative vascular waveforms, and bile production. The left lateral segment graft was implanted using piggyback caval implantation and Roux-en-Y biliary reconstruction. Postoperative Doppler demonstrated patent vessels. Early findings in both recipients demonstrated vascular patency and graft recovery. This initial experience demonstrates the technical feasibility of incorporating VitaSmart hypothermic machine perfusion into split liver transplantation and highlights its potential role in expanding split graft utilization.

PMID 42876352
Read full article →
PubMedTransplantation2026-10-15

Meta-analysis of short-term clinical and survival outcomes of full-left-full-right split liver transplantation for two recipients: Erratum.

Hajibandeh Shahin S, Hajibandeh Shahab S, Ahmad Farhan F, Haldar Debashis D et al.

PMID 42875860
Read full article →
PubMedMedical physics2026-10-15

Low-spatial-frequency perception enhancing dynamic convolutional network for system matrix recovery in magnetic particle imaging.

Dong Zhen Z, An Yu Y, Li Guanghui G, Guo Lishuang L et al.

Magnetic particle imaging (MPI) is an emerging molecular imaging modality known for its high sensitivity and long-term tracking. System matrix (SM)-based image reconstruction is one of the most important reconstruction methods for MPI. However, MPI reconstruction based on the measured SM is limited by the requirement of voxel-stepwise precise calibration of system function within the field of view (FOV), which is time-consuming and noise-prone. Additionally, any changes in system properties require recalibrating the SM. This hinders the clinical translation and practical application of MPI. To address these limitations, we propose a low-spatial-frequency perception enhancing dynamic convolutional network (LPEDCN) to recover SMs for accelerating calibration. Specifically, we observe and reveal a positive correlation between the percentage of low-spatial-frequency energy and the signal-to-noise ratio (SNR) in the spatial Fourier transform (SFT) domain of real-world SM rows. Based on this prior, we design a low-spatial-frequency perception enhancement (LPE) joint loss to suppress high-frequency noise during model training. We also introduce a context-modulated dynamic convolution (CMDC) to capture long-range contextual features. We evaluate LPEDCN on simulated (training set: 60 SMs split into 107880 SM-row slices; validation set: 20 SMs split into 37520 slices; test set: 20 SMs split into 32660 slices; with no overlap between sets), public real-world OpenMPI (training set: 1 SM split into 101861 SM-row slices; validation set: 1 SM split into 62863 slices; test set: 1 SM split into 85347 slices; with no overlap between sets), and in-house (test set: 2 SMs split into 225 and 272 slices, respectively) datasets. SM recovery accuracy is evaluated by normalized root-mean-square error (nRMSE), and the reconstruction quality is evaluated by peak signal-to-noise ratio (PSNR) and structural similarity index measure (SSIM). We assess LPEDCN by comparing it with seven state-of-the-art (SOTA) methods. Statistical significance is evaluated using two-tailed t-tests with p < 0.05 after False Discovery Rate (FDR) correction, and practical significance is assessed using Cohen's d for effect size. LPEDCN not only accelerates SM calibration in MPI, but also exhibits higher accuracy in SM recovery and better quality in image reconstruction compared to SOTA methods. For the core SM recovery metric nRMSE, LPEDCN significantly outperforms SOTA methods (p < 0.05, FDR corrected) for 2×, 4×, and 8× super-resolution (SR), respectively, with effect size values of 0.23-1.02 on the simulated dataset and 0.06-45.63 on the public real-world OpenMPI dataset. For the image reconstruction metrics PSNR and SSIM, LPEDCN is significantly superior to SOTA methods (p < 0.05, FDR corrected) for 2×, 4×, and 8× SR, respectively, with effect size values of 0.45-8.68 on the simulated dataset, and 0.10-4.65 on the OpenMPI dataset. These quantitative results consistently verify that LPEDCN yields practically meaningful performance improvements. Additionally, LPEDCN greatly reduces the SM calibration time and achieves excellent high-resolution reconstruction images. LPEDCN holds practical promise for improving MPI calibration efficiency.

PMID 42875938
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about influenza vaccine